ESMO 2016 conference (Oct 7-11) 3 presidential sessions (niraparib/ovarian)

Medscape 

Taking place from October 7 to 11 in Copenhagen, this is the largest oncology meeting in Europe, say the organizers, who are expecting more than 20,000 attendees listening to 1600 approved abstracts, of which 50 will be reporting late-breaking trials. This will form part of 21 tumor tracks covering all areas of oncology, from basic science to clinical activities and public health.
Andrés Cervantes, MD, professor of medicine at the University of Valencia, Spain, and Scientific Committee chair for ESMO 2016, explained that so many trials are being reported at the meeting that are predicted to have an impact on clinical practice that there will be not one but three presidential sessions.

The first presidential symposium takes place on Saturday, October 8, and will discuss three abstracts that feature new investigational agents. The first will discuss results from the MONALEESA-2 study, which looked at the investigational CDK4/6 inhibitor ribociclib (formerly LEE011, Novartis) used with letrozole (Femara, Novartis) in postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer. In the same session, results will be presented from a randomized study on the use of a new PARP (poly [ADP-ribose] polymerase) inhibitor niraparib, which is under development by Tesaro, in patients with platinum-sensitive ovarian cancer.